StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.58+0.00 (0.00%)

Close on Nov 13, 2026Market cap $131.79MP/E –Yield –

Pyxis Oncology statistics

59 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Mar 22, 2027 (estimated, before the open)
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2026
Share price as of
Nov 13, 2026

Valuation ratiosIndustry

Market Cap
$131.79M
$272.32M
Enterprise Value
$76.18M
$146.23M
PB Ratio
3.19
2.00
P/TBV Ratio
3.19
2.22

Share statisticsIndustry

Shares Change (YoY)
11.0%
10.8%
Shares Change (QoQ)
31.6%
0.50%
Float
66M
49M
Shares Held by Insiders
20.4%
11.7%
Shares Held by Institutions
40.9%
56.4%

Short sellingIndustry

Short Interest
5M
–
Short Interest Change
4.12%
-0.80%
Short % of Float
6.81%
9.01%
Short % of Shares Outstanding
5.43%
6.30%
Days to Cover
5.82
5.15

Stock price statisticsIndustry

52-Week High
$5.55
–
52-Week Low
$1.03
–
20-Day Moving Average
$1.72
–
50-Day Moving Average
$2.33
–
200-Day Moving Average
$2.16
–
Average True Range (14)
$0.15
–
Price Change (1 Week)
-4.82%
-1.15%
Price Change (1 Month)
-12.2%
-4.87%
Price Change (3 Months)
-47.7%
-21.0%
Price Change (6 Months)
-30.7%
-20.6%
Price Change (YTD)
37.4%
-23.6%
Price Change (1 Year)
-63.8%
-22.4%
Price Change (3 Years)
1.94%
-29.5%
Price Change (5 Years)
-86.6%
-77.9%
Average Volume (10 Days)
768,067
–
Average Volume (20 Days)
771,788
–
Average Volume (90 Days)
1M
–
Relative Volume
0.32
0.70
Relative Strength Index (14)
34.5
43.4
Volatility (1 Year)
123.7%
80.1%
Beta (5 Years)
1.61
1.07

Returns on capitalIndustry

Return on Equity (ROE)
-157.5%
-49.9%
Return on Assets (ROA)
-95.1%
-40.6%
Return on Capital Employed (ROCE)
-156.9%
-37.9%

Financial positionIndustry

Current Ratio
2.96
3.30
Quick Ratio
2.79
2.39

EfficiencyIndustry

Profits Per Employee
-$1.55M
-$689.41K
Employee Count
56
74
WACC
13.1%
10.2%

Income statement (TTM)Industry

Operating Income
-$89.17M
-$21.37M
Net Income
-$86.71M
-$22.35M
EBITDA
-$85.21M
-$17.21M
EPS (Diluted)
-$1.30
-$0.76

Balance sheetIndustry

Net Cash (Debt)
$55.60M
$17.76M
Net Cash Per Share
$0.67
$0.80
Equity (Book Value)
$41.32M
$53.89M
Book Value Per Share
$0.50
$1.50
Tangible Book Value
$41.32M
$27.13M
Working Capital
$39.19M
$79.99M

Cash flow (TTM)Industry

Operating Cash Flow
-$70.93M
-$12.38M

Dividends and yieldsIndustry

Earnings Yield
-65.8%
-21.8%

Scores and fair valueIndustry

Altman Z-Score
-10.32
0.23
Piotroski F-Score
1
4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodPYXSS&P 500DifferencePYXS per yearS&P 500 per year
1 month-14.6%-3.0%−11.6 pts
3 months-47.5%-2.8%−44.7 pts
Year to date+37.4%+11.5%+25.9 pts
1 year-64.7%+13.5%−78.2 pts
3 years+1.3%+77.7%−76.4 pts+0.4%+21.1%
5 years-86.6%+72.6%−159.2 pts-33.1%+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

5M PYXS shares were sold short on Oct 30, 2026, up 4.1% from the previous report, or 6.81% of the shares available to trade. At recent volumes it would take 5.8 days to buy them back. Over the last 20 sessions, 55.5% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20264,525,205+4.1%777,6195.8
Oct 15, 20264,345,953-11.1%1,253,8093.5
Sep 30, 20264,886,652+4.4%1,207,8324.0
Sep 15, 20264,678,522+17.9%1,282,0713.6
Aug 31, 20263,968,105-10.3%569,9637.0
Aug 14, 20264,425,542+6.1%2,219,4792.0
Jul 31, 20264,172,154+28.2%996,5324.2
Jul 15, 20263,253,653+42.1%1,045,8453.1
Jun 30, 20262,289,798+13.6%1,838,5871.3
Jun 15, 20262,015,710+15.7%415,4784.8
May 29, 20261,741,743-3.8%607,7112.9
May 15, 20261,809,793-8.9%855,9562.1

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?